Evidence map›Paper›PMID 42647168›Full record

ArticleCell reports2026

Surface and global proteomics identify ROR2 and other proteins as potentially actionable immunotherapeutic targets in osteosarcoma.

Brian Mooney, Xiaojie Chu, Gian Luca Negri, Michael M Lizardo, Harley Song, Alison Marsh, Alberto Delaidelli, Yue Z Huang, Melanie Rouleau, Sandra E Spencer and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Brian MooneyDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada.
Xiaojie ChuCenter for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA, USA.
Gian Luca NegriDepartment of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada.
Michael M LizardoDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Harley SongDepartment of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada.
Alison MarshDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Alberto DelaidelliDepartment of Pathology, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Yue Z HuangDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Melanie RouleauDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Sandra E SpencerDepartment of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada.
Rawan ShraimCenter for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Amber K HamiltonCenter for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Sruthi MageshDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.
Wendong ZhangDivision of Pediatrics, Children's Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yogesh BudhathokiCenter for Childhood Cancer Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA.
Matthew V CannonCenter for Childhood Cancer Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA.
Ryan RobertsCenter for Childhood Cancer Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA.
Richard GorlickDivision of Pediatrics, Children's Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alejandro Sweet-CorderoDivision of Pediatric Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Sharon J DiskinCenter for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
John M MarisCenter for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Wei LiCenter for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA, USA.
Gregg B MorinDepartment of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Poul H SorensenDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: poul.sorensen@ubc.ca.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG U24 Funding 2026-2027U24CA196173 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Mignon Lee-Cheun Loh, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$62.5M
Understanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1M
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-VirotherapyU54CA232561 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI CRIPE, TIMOTHY P · 2019 to 2023
$12.1M
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesR35CA220500 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$8.7M
NCI NIH HHS R35 CA220500NCI NIH HHS U10 CA180886NCI NIH HHS U24 CA196173NCI NIH HHS U54 CA232561NCI NIH HHS U54 CA232568
6 · The paper itself

Abstract

Osteosarcoma (OS) is the most common human primary bone cancer, primarily affecting children and young adults. While the survival rate of patients diagnosed with localized OS is ∼65%, this decreases to ∼20% for patients with metastatic disease, and recurrent disease remains largely incurable. Therefore, identifying new therapeutic strategies is urgently needed for metastatic and refractory OS. This study analyzes the surfaceomes and global proteomes of 22 unique OS patient-derived xenografts (PDXs) using mass spectrometry to identify surface proteins for potential immunotherapeutic targeting. Both methods identify known OS-associated surface candidates including LRRC15, MMP14, MRC2, and CADM1, and several poorly characterized targets, including ROR2 and TMEM119. Both ROR2 and TMEM119 display robust expression in OS tissues but only limited or no expression in normal pediatric tissues, and loss of both targets reduces the migration of OS cells. These data provide a resource of surface proteins as potential immunotherapeutic targets in OS.

Indexed as

Bone NeoplasmsImmunotherapyOsteosarcomaProteomicsReceptor Tyrosine Kinase-like Orphan ReceptorsAnimalsCell Line, TumorCell MovementFemaleHumansMembrane ProteinsMiceMembrane ProteinsReceptor Tyrosine Kinase-like Orphan ReceptorsROR2 protein, humanADCsantibody drug conjugatesCP: cancerCP: immunologyimmunotherapyosteosarcomaproteomicsROR2TMEM119

Identifiers

PMID42647168
PMCPMC13671662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.